Myofibrillar myopathy type 6 (MFM6) is a rare genetic muscle disorder that leads to severe muscle weakness and a drastically ...

Cenrifki prevents MS disease progression and Itvisma delivers a healthy gene-to-cell nuclei, addressing the root cause of SMA.

The trial plans to enrol approximately 518 participants.

Inclusion body myositis (IBM) is a slowly progressive muscle-wasting disease that typically starts with weakness in the hands and upper legs and often leads to difficulty swallowing. There is no cure, ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, will be presenting the results ...

Blocking the JNK pathway eased disease severity and extended survival in SMA mice, pointing to a potential new treatment ...

An international research team with the participation of researchers from the University Medical Center Göttingen (UMG), ...

Mayo Clinic's Translational Neuromuscular Disease Research Lab led by Nathan P. Staff, M.D., Ph.D., studies the biological ...

Muscle loss is common among people taking GLP-1 medications. Full-body strength training can help preserve muscle mass and ...

Minnesota United have denied rumours that midfielder James Rodriguez is suffering from a potentially life-threatening muscle-wasting condition. The Colombia international returned to the club's ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock, a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, ...

Apitegromab BLA resubmission includes Catalent Indiana LLC (part of Novo Nordisk) and second U.S.-based fill-finish facility, aligned with FDA guidance from March 3, 2026 Type C meeting FDA and Novo ...